The New Science

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized controlled trial


Findings from this large, long-term, randomized controlled trial suggest that a multidomain intervention could improve or maintain cognitive functioning in at-risk elderly people from the general population. READ THE STUDY

Reversal of Cognitive Decline: 100 Patients

100 patients, treated by several different physicians, with documented improvement in cognition.  READ THE STUDY

Reversal of cognitive decline in Alzheimer's disease

Patients who had had to discontinue work were able to return to work, and those struggling at work were able to improve their performance. The patients, their spouses, and their co-workers all reported clear improvements. Here we report the results from quantitative MRI and neuropsychological testing in ten patients with cognitive decline, nine ApoE4+ and one ApoE4. The magnitude of the improvement is unprecedented with far-reaching implications for treatment of Alzheimer's disease, MCI, and SCI.  READ THE STUDY

APOE ε4, the door to insulin-resistant dyslipidemia and brain fog? A case study

This case study evaluates the effects of a 10-week clinically prescribed ketogenic diet (KD) with a 68-year-old male, heterozygous APOE ε4 carrier, with a dual diagnosis of mild AD and type 2 diabetes (T2DM). Ketogenic protocols seem to exert powerful modulatory effects on the most treatment-resistant conditions including obese carriers of the APOE ε4 variant who suffer from comorbid mild cognitive impairment and T2DM. Previous clinical trials have demonstrated the neurological efficacy of the KD. The significant improvements in memory, executive function, MetS pathologies, and cerebral metabolic rate demonstrated in this case study are reproducible and could be easily translated to a general population of MetS patients with self-reported impairments in cognition. READ THE STUDY

Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic.


Type 3 Alzheimer's disease is the result of exposure to specific toxins.  READ THE STUDY



Metabolic profiling distinguishes three subtypes of Alzheimer's disease.


Metabolic profiling reveals three Alzheimer's disease subtypes. The first is inflammatory, in which markers such as hs-CRP and globulin:albumin ratio are increased. The second type is non-inflammatory, in which these markers are not increased, but other metabolic abnormalities are present. The third type is a very distinctive clinical entity that affects relatively young individuals, extends beyond the typical Alzheimer's disease initial distribution to affect the cortex widely, is characterized by early non-amnestic features such as dyscalculia and aphasia, is often misdiagnosed or labeled atypical Alzheimer's disease, typically affects ApoE4-negative individuals, and is associated with striking zinc deficiency.   READ THE STUDY


All information, content, and material of this website, or from this website, is for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider.


© 2019 Age On Purpose, LLC               Privacy Policy           Terms of Use         Disclaimer